Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses

Expert Review of Vaccines

Volumn 7, Issue 4, 2008, Pages 417-429

  Swenson, Dana L ^a   Warfield, Kelly L ^a   Larsen, Tom ^a   Alves, D Anthony ^a   Coberley, Sadie S ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Antibody; Ebola; Filovirus; Marburg; Nonhuman primate; Protective immunity; Vaccine; Virus like particle

Indexed keywords

INACTIVATED MARBURG VIRUS VACCINE; INACTIVATED VIRUS VACCINE; MARBURG VIRUS LIKE PARTICLE VACCINE; RIBI VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GUINEA PIG; HISTOPATHOLOGY; HUMORAL IMMUNITY; MACACA; MALE; MAMMAL CELL; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINATION; VIREMIA; VIRUS HEMORRHAGIC FEVER; VIRUS ISOLATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; GUINEA PIGS; MACACA FASCICULARIS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MOLECULAR SEQUENCE DATA; PLAQUE ASSAY; SEQUENCE ALIGNMENT; SURVIVAL ANALYSIS; VACCINES, INACTIVATED; VIRAL VACCINES; VIREMIA; VIROSOMES;

EID: 43249105784     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.4.417     Document Type: Article

References (41)

1. Slenczka W, Klenk HD. Forty years of Marburg virus. J. Infect. Dis. 196(Suppl. 2), S131-S135 (2007).
2. Hevey M, Negley D, Vanderzanden L et al. Marburg virus vaccines, comparing classical and new approaches. Vaccine 20, 586-593 (2002).
3. Ignat'ev GM, Strel'tsova MA, Agafonov AP, Zhukova NA, Kashentseva EA, Vorob'eva MS. [The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus]. Vopr. Virusol. 39(1), 13-17 (1994).
4. Ignatev GM, Agafonov AP, Strel'tsova MA et al. A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus. Vopr. Virusol. 36, 421-423 (1991).
5. Ignatyev GM, Agafonov AP, Streltsova MA, Kashentseva EA. Inactivated Marburg virus elicits a nonprotective immune response in rhesus monkeys. J. Biotechnol. 44(1-3), 111-118 (1996).
6. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251(1), 28-37 (1998).
7. Jones SM, Feldmann H, Stroher U et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11(7), 786-790 (2005).
8. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80(19), 9659-9666 (2006).
9. Wang D, Hevey M, Juompan LY et al. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 353(2), 324-332 (2006).
10. Swenson DL, Wang D, Luo M et al. Complete protection of nonhuman primates against multi-strain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 15(3), 460-467 (2008).
11. Hart MK. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33, 583-595 (2003).
12. Warfield KL, Swenson DL, Demmin G, Bavari S. Filovirus-like particles as vaccines and discovery tools. Expert Rev. Vaccines 4(3), 429-440 (2005).
13. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239(1), 206-216 (1997).
14. Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21(25-26), 4071-4080 (2003).
15. Swenson DL, Warfield KL, Kuehl K et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol. Med. Microbiol. 40(1), 27-31 (2004).
16. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23(23), 3033-3042 (2005).
17. Bavari S, Bosio CM, Wiegand E et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195(5), 593-602 (2002).
18. Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine 22(25-26), 3495-3502 (2004).
19. Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. J. Clin. Microbiol. 13(4), 791-793 (1981).
20. Lofts LL, Ibrahim MS, Negley DL, Hevey MC, Schmaljohn AL. Genomic differences between guinea pig lethal and nonlethal Marburg virus variants. J. Infect. Dis. 196(Suppl. 2), S305-S312 (2007).
21. Warfield KL, Posten NA, Swenson DL et al. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J. Infect. Dis. 196(Suppl. 2), S421-S429 (2007).
22. National Research Council. Guide for the Care and Use of Laboratory Animals (1996).
23. Warfield KL, Swenson DL, Olinger GG et al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2(1), e1 (2006).
24. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196(Suppl. 2), S430-S437 (2007).
25. + T cells. J. Virol. 76(18), 9176-9185 (2002).
26. Simpson DI, Zlotnik I, Rutter DA. Vervet monkey disease: experimental infection of guinea pigs and monkeys with the causative agents. Br. J. Exp. Pathol. 49, 458-464 (1968).
27. Zlotnik I. Marburg agent disease: pathology. Trans. R. Soc. Trop. Med. Hyg. 63, 310-323 (1969).
28. Robin Y, Bres P, Camain R. Passage of Marburg virus in guinea pigs. In: Marburg Virus. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA 117-122 (1971).
29. Connolly BM, Steele KE, Davis KJ et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179(Suppl. 1), S203-S217 (1999).
30. Volchkov VE, Chepurnov AA, Volchkova VA, Ternovoj VA, Klenk HD. Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277(1), 147-155 (2000).
31. Ryabchikova E, Kolesnikova L, Smolina M et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch. Virol. 141(5), 909-921 (1996).
32. Ryabchikova E, Strelets L, Kolesnikova L, P'yankov O, Sergeev A. Respiratory Marburg virus infection in guinea pigs. Arch. Virol. 141(11), 2177-2190 (1996).
33. Slenczka W, Shu HL, Piepenberg G, Siegert R. Detection of the antigen of the "Marburg virus" in the organs of infected guinea-pigs by immunofluorescence. Ger. Med. Mon. 13(11), 524-529 (1968).
34. Gedigk P, Bechtelsheimer H, Korb G. [Pathological anatomy of the "Marburg virus" disease (the so-called "Marburg monkey disease")]. Dtsch. Med. Wochenschr. 93(12), 590-601 (1968).
35. Shu HL, Siegert R, Slenczka W. The pathogenesis and epidemiology of the "Marburg-virus" infection. Ger. Med. Mon. 14(1), 7-10 (1969).
36. Haas R, Maass G. Experimental infection of monkeys with the Marburg virus. In: Marburg Virus. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA 136-143 (1971).
37. Murphy FA, Simpson DI, Whitfield SG, Zlotnik I, Carter GB. Marburg virus infection in monkeys. Ultrastructural studies. Lab. Invest. 24(4), 279-291 (1971).
38. Stille W, Bohle E. Clinical course and prognosis of Marburg virus ("green-monkey") disease. In: Marburg Virus Disease. Martini GA, Siegart R (Eds). Springer-Verlag, NY, USA 10-18 (1971).
39. Warfield KL, Alves DA, Bradfute SB et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol. J. 4(1), 108 (2007).
40. + T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 175(2), 1184-1191 (2005).
41. 101 US FDA - Gardasil® product approval information www.fda.gov/cber/products/gardasil.ht